

Yoshiko Atsuta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9290260/publications.pdf>

Version: 2024-02-01

164
papers

4,711
citations

117625

34
h-index

118850

62
g-index

168
all docs

168
docs citations

168
times ranked

3745
citing authors

#	ARTICLE	IF	CITATIONS
1	One million haemopoietic stem-cell transplants: a retrospective observational study. <i>Lancet Haematology</i> , 2015, 2, e91-e100.	4.6	329
2	Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. <i>International Journal of Hematology</i> , 2007, 86, 269-274.	1.6	282
3	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. <i>Blood</i> , 2017, 129, 2347-2358.	1.4	268
4	Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). <i>International Journal of Hematology</i> , 2016, 103, 3-10.	1.6	261
5	Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. <i>Blood</i> , 2010, 116, 1369-1376.	1.4	255
6	Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. <i>Blood</i> , 2009, 113, 1631-1638.	1.4	210
7	Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. <i>Blood</i> , 2015, 125, 1189-1197.	1.4	185
8	Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System. <i>International Journal of Hematology</i> , 2007, 86, 269-274.	1.6	127
9	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. <i>Blood</i> , 2012, 119, 2141-2148.	1.4	110
10	Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 330-338.	2.0	100
11	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia. <i>Haematologica</i> , 2013, 98, 814-822.	3.5	77
12	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. <i>Blood</i> , 2013, 121, 3095-3102.	1.4	70
13	Comparison of Unrelated Cord Blood Transplantation and HLA-Mismatched Unrelated Bone Marrow Transplantation for Adults with Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 780-787.	2.0	67
14	Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1183-1189.	2.0	63
15	Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFβ-MYH11. <i>Blood Advances</i> , 2020, 4, 66-75.	5.2	63
16	Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1785-1790.	2.0	61
17	Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. <i>Blood</i> , 2009, 113, 2096-2103.	1.4	60
18	Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. <i>American Journal of Hematology</i> , 2016, 91, E284-92.	4.1	59

#	ARTICLE	IF	CITATIONS
19	Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. <i>Blood</i> , 2012, 119, 2409-2416.	1.4	57
20	Hematopoietic Engraftment in Recipients of Unrelated Donor Umbilical Cord Blood Is Affected by the CD34+ and CD8+ Cell Doses. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 822-830.	2.0	55
21	Impact of a single human leucocyte antigen (<sc>HLA</sc>) allele mismatch on the outcome of unrelated bone marrow transplantation over two time periods. A retrospective analysis of 3003 patients from the <sc>HLA W</sc>orking <sc>G</sc>roup of the <sc>J</sc>apan <sc>S</sc>ociety for <sc>B</sc>lood and <sc>M</sc>arrow <sc>T</sc>ransplantation. <i>British Journal of Haematology</i> , 2013, 161, 566-577.	2.5	52
22	Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABLâ€‘positive acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 2325-2332.	1.4	52
23	Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 601-609.	1.3	51
24	â€‘Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registriesâ€™. <i>Bone Marrow Transplantation</i> , 2019, 54, 1179-1188.	2.4	51
25	Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. <i>Blood</i> , 2015, 126, 415-422.	1.4	49
26	Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 68-75.	2.4	49
27	Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 247-254.	2.0	46
28	Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry. <i>International Journal of Hematology</i> , 2010, 91, 855-864.	1.6	45
29	Peripheral Blood as a Preferable Source of Stem Cells for Salvage Transplantation in Patients with Graft Failure after Cord Blood Transplantation: A Retrospective Analysis of the Registry Data of the Japanese Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1407-1414.	2.0	44
30	Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. <i>Haematologica</i> , 2016, 101, 1592-1602.	3.5	41
31	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 744-751.	2.0	41
32	Unit selection for umbilical cord blood transplantation for adults with acute myeloid leukemia in complete remission: a Japanese experience. <i>Bone Marrow Transplantation</i> , 2019, 54, 1789-1798.	2.4	39
33	Improvement of early mortality in singleâ€‘unit cord blood transplantation for Japanese adults from 1998 to 2017. <i>American Journal of Hematology</i> , 2020, 95, 343-353.	4.1	39
34	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	7.2	36
35	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2029-2033.	2.0	34
36	Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2079-2087.	2.0	34

#	ARTICLE	IF	CITATIONS
37	Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 519-528.	2.0	34
38	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosomeâ€­positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2019, 110, 3255-3266.	3.9	32
39	Impact of HLA Mismatch Direction on the Outcome of Unrelated Bone Marrow Transplantation: A Retrospective Analysis from the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 305-311.	2.0	31
40	Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 231-238.	2.0	29
41	Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. <i>Bone Marrow Transplantation</i> , 2021, 56, 1126-1133.	2.4	27
42	Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. <i>Haematologica</i> , 2016, 101, 644-652.	3.5	26
43	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. <i>Annals of Hematology</i> , 2020, 99, 1351-1360.	1.8	26
44	Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 662-667.	2.0	25
45	Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. <i>Haematologica</i> , 2014, 99, e264-e268.	3.5	25
46	Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of <sc>CD</sc>34â€­positive cells or total nucleated cells?. <i>British Journal of Haematology</i> , 2019, 185, 166-169.	2.5	25
47	Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. <i>Blood Advances</i> , 2019, 3, 105-115.	5.2	25
48	Impact of pretransplant donor-specific anti-HLA antibodies on cord blood transplantation on behalf of the Transplant Complications Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 722-728.	2.4	25
49	Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1515-1522.	2.0	24
50	Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1447-1454.	2.0	23
51	Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 334.e1-334.e11.	1.2	23
52	Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence. <i>Bone Marrow Transplantation</i> , 2021, 56, 2355-2366.	2.4	23
53	Autologous hematopoietic cell transplantation for acute promyelocytic leukemia in second complete remission: outcomes before and after the introduction of arsenic trioxide. <i>Leukemia and Lymphoma</i> , 2017, 58, 1061-1067.	1.3	22
54	Double-Unit Cord Blood Transplantation after Myeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Phase II Study in Japan. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 812-819.	2.0	21

#	ARTICLE	IF	CITATIONS
55	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2322-2329.	2.0	21
56	Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study. <i>British Journal of Haematology</i> , 2015, 168, 463-466.	2.5	20
57	Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2009-2016.	2.0	19
58	The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2372-2377.	2.0	19
59	Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades. <i>Bone Marrow Transplantation</i> , 2019, 54, 578-586.	2.4	17
60	Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan. <i>International Journal of Hematology</i> , 2020, 111, 93-102.	1.6	17
61	Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2105-2114.	2.0	17
62	Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1784-1795.	2.4	17
63	Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1004-1012.	2.4	16
64	Effect of Cytomegalovirus Reactivation With or Without Acute Graft-Versus-Host Disease on the Risk of Nonrelapse Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, e620-e628.	5.8	16
65	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1132-1138.	7.2	16
66	Improved trends in survival and engraftment after single cord blood transplantation for adult acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	16
67	Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. <i>Bone Marrow Transplantation</i> , 2018, 53, 478-482.	2.4	15
68	Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia. <i>American Journal of Hematology</i> , 2017, 92, 902-908.	4.1	14
69	Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. <i>International Journal of Hematology</i> , 2019, 109, 175-186.	1.6	14
70	A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1266-1274.	2.4	14
71	Differential Effect of Graft-versus-Host Disease on Survival in Acute Leukemia according to Donor Type. <i>Clinical Cancer Research</i> , 2021, 27, 4825-4835.	7.0	14
72	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 1317-1325.	2.4	14

#	ARTICLE	IF	CITATIONS
73	Comparison of transplantation with reduced and myeloablative conditioning for children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 1352-1354.	1.4	13
74	Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 832-839.	2.0	13
75	Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. <i>Annals of Hematology</i> , 2019, 98, 1367-1381.	1.8	13
76	Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>British Journal of Haematology</i> , 2020, 190, 84-92.	2.5	13
77	Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 387-394.	2.4	13
78	A Safety and Efficacy Study of Medium-Dose Etoposide, Cyclophosphamide and Total Body Irradiation Conditioning Before Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia. <i>Transplantation Direct</i> , 2015, 1, 1-7.	1.6	12
79	Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 300-309.	2.0	12
80	Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 307-315.	2.0	12
81	Effects of Haplotype Matching on Outcomes after Adult Single-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 509-518.	2.0	11
82	Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. <i>International Journal of Hematology</i> , 2018, 107, 211-221.	1.6	10
83	Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission. <i>Bone Marrow Transplantation</i> , 2019, 54, 2004-2012.	2.4	9
84	Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation. <i>Blood Cancer Journal</i> , 2019, 9, 31.	6.2	9
85	Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1430-1437.	2.4	9
86	Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2020, 55, 1399-1409.	2.4	9
87	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>International Journal of Hematology</i> , 2021, 113, 832-839.	1.6	9
88	Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients. <i>Bone Marrow Transplantation</i> , 2021, 56, 2510-2517.	2.4	9
89	Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. <i>Bone Marrow Transplantation</i> , 2021, 56, 2779-2787.	2.4	9
90	Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. <i>American Journal of Hematology</i> , 2022, 97, 780-790.	4.1	9

#	ARTICLE	IF	CITATIONS
91	Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation. <i>Hematological Oncology</i> , 2019, 37, 586-594.	1.7	8
92	Effects of Acute and Chronic Graft-versus-myelodysplastic Syndrome on Long-term Outcomes Following Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2020, 26, 6483-6493.	7.0	8
93	Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1363-1370.	2.0	8
94	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	2.4	8
95	Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, 86-90.	2.5	7
96	Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. <i>Bone Marrow Transplantation</i> , 2020, 55, 2008-2016.	2.4	7
97	Reduced leukemia relapse through cytomegalovirus reactivation in killer cell immunoglobulin-like receptor-ligand-mismatched cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1352-1363.	2.4	7
98	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. <i>International Journal of Hematology</i> , 2021, 113, 840-850.	1.6	7
99	Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. <i>Bone Marrow Transplantation</i> , 2021, 56, 2302-2304.	2.4	7
100	Clinical Impacts of Germline <i>DDX41</i> Mutations on Myeloid Neoplasms. <i>Blood</i> , 2020, 136, 38-40.	1.4	7
101	Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT. <i>JCI Insight</i> , 2021, 6, .	5.0	7
102	Increasing access to hematopoietic cell transplantation in Latin America: results of the 2018 LABMT activity survey and trends since 2012. <i>Bone Marrow Transplantation</i> , 2022, 57, 881-888.	2.4	7
103	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2392-2397.	1.3	6
104	Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. <i>International Journal of Hematology</i> , 2020, 112, 841-850.	1.6	6
105	Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin. <i>Cell Transplantation</i> , 2020, 29, 096368972097656.	2.5	6
106	Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study. <i>Bone Marrow Transplantation</i> , 2021, 56, 2125-2136.	2.4	6
107	Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2231-2240.	2.4	6
108	Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation—A Matched-Pair Analysis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 995.e1-995.e6.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Effect of Multiple HLA Locus Mismatches on Outcomes after Single Cord Blood Transplantation. Transplantation and Cellular Therapy, 2022, 28, 398.e1-398.e9.	1.2	6
110	Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes. Biology of Blood and Marrow Transplantation, 2016, 22, 2031-2037.	2.0	5
111	Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis. Leukemia and Lymphoma, 2016, 57, 2077-2083.	1.3	5
112	Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan. Leukemia Research, 2019, 87, 106263.	0.8	5
113	Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. Bone Marrow Transplantation, 2020, 55, 249-252.	2.4	5
114	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Annals of Hematology, 2020, 99, 2393-2404.	1.8	5
115	Unrelated cord blood transplantation with myeloablative conditioning for pediatric acute lymphoblastic leukemia in remission: prognostic factors. Bone Marrow Transplantation, 2021, 56, 357-367.	2.4	5
116	Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplantation, 2022, 57, 43-50.	2.4	5
117	Autologous hematopoietic cell transplantation during second or subsequent complete remission of acute promyelocytic leukemia: a prognostic factor analysis. Bone Marrow Transplantation, 2022, 57, 78-82.	2.4	5
118	Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. Bone Marrow Transplantation, 2022, 57, 479-486.	2.4	5
119	Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. Transplantation and Cellular Therapy, 2022, 28, 209.e1-209.e9.	1.2	5
120	Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. Blood Advances, 2022, 6, 1895-1903.	5.2	5
121	Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia, 2022, 36, 1361-1370.	7.2	5
122	Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. British Journal of Haematology, 2019, 186, e219-e223.	2.5	4
123	Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. Bone Marrow Transplantation, 2020, 55, 1955-1965.	2.4	4
124	Effect of extramedullary disease on allogeneic hematopoietic cell transplantation for pediatric acute myeloid leukemia: a nationwide retrospective study. Bone Marrow Transplantation, 2021, 56, 1859-1865.	2.4	4
125	Adding melphalan to fludarabine and a myeloablative dose of busulfan improved survival after allogeneic hematopoietic stem cell transplantation in a propensity score-matched cohort of hematological malignancies. Bone Marrow Transplantation, 2021, 56, 1691-1699.	2.4	4
126	Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 2771-2778.	2.4	4

#	ARTICLE	IF	CITATIONS
127	Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2964-2974.	2.4	4
128	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3008-3015.	2.4	4
129	Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1462-1466.	2.4	4
130	Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 326.e1-326.e10.	1.2	4
131	Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 744-753.	1.6	4
132	Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2482-2489.	2.0	3
133	HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. <i>Haematologica</i> , 2019, 104, 1055-1061.	3.5	3
134	Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 400-410.	2.4	3
135	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2183-2193.	2.4	3
136	Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in Japan. <i>Bone Marrow Transplantation</i> , 2021, 56, 2173-2182.	2.4	3
137	Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2410-2422.	2.4	3
138	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapyâ€refractory or relapsed disease prior to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 403-413.	2.5	3
139	Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2020, 55, 2098-2108.	2.4	3
140	Retrospective Analysis of Autologous Stem Cell Transplantation for AL Amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 76-82.	1.2	3
141	Long-term follow-up of patients with ATL after autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 323-325.	2.4	3
142	Prognostic Factors for Outcomes of Allogeneic HSCT for Children and Adolescents/Young Adults With CML in the TKI Era. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 376-389.	1.2	3
143	Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Cytotherapy</i> , 2022, 24, 954-961.	0.7	3
144	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. <i>Cytotherapy</i> , 2022, 24, 1013-1025.	0.7	3

#	ARTICLE	IF	CITATIONS
145	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation—a report from the Adult Acute Lymphoblastic Leukemia Working Group of the ISTCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2842-2848.	2.4	2
146	Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. <i>Blood Cancer Journal</i> , 2021, 11, 159.	6.2	2
147	Impact of HLA disparity on the risk of overall mortality in patients with grade II–IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2990-2996.	2.4	2
148	Altered effect of killer immunoglobulin-like receptor–ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 3059-3067.	2.4	2
149	Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies. <i>Bone Marrow Transplantation</i> , 2022, 57, 243-251.	2.4	2
150	Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 153.e1-153.e11.	1.2	2
151	Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 323.e1-323.e9.	1.2	2
152	Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch. <i>Bone Marrow Transplantation</i> , 2022, 57, 1171-1179.	2.4	2
153	Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation?. <i>British Journal of Haematology</i> , 2020, 189, e56-e60.	2.5	1
154	Does one model fit all? Predicting non-relapse mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1720-1722.	2.4	1
155	Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2021, 56, 3016-3023.	2.4	1
156	Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 1412-1424.	5.2	1
157	Human leukocyte antigen (HLA) haplotype matching in unrelated single HLA allele mismatch bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 407-415.	2.4	1
158	Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 161.e1-161.e10.	1.2	1
159	Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 504.e1-504.e7.	1.2	1
160	Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 598.e1-598.e8.	1.2	1
161	Individual HLAs influence immunological events in allogeneic stem cell transplantation from HLA-identical sibling donors. <i>Bone Marrow Transplantation</i> , 2021, 56, 646-654.	2.4	0
162	Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm. <i>Blood</i> , 2019, 134, 2008-2008.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents. Bone Marrow Transplantation, 2022, , .	2.4	0
164	The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, , .	1.2	0